BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takahashi N, Yamada Y, Taniguchi H, Fukahori M, Sasaki Y, Shoji H, Honma Y, Iwasa S, Takashima A, Kato K. Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer. BMC Res Notes. 2014;7:271. [PMID: 24774510 DOI: 10.1186/1756-0500-7-271] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Watanabe M, Kuwata T, Setsuda A, Tokunaga M, Kaito A, Sugita S, Tonouchi A, Kinoshita T, Nagino M. Molecular and pathological analyses of gastric stump cancer by next-generation sequencing and immunohistochemistry. Sci Rep 2021;11:4165. [PMID: 33603111 DOI: 10.1038/s41598-021-83711-1] [Reference Citation Analysis]
2 Sudo K, Yamada Y. Advancing pharmacological treatment options for advanced gastric cancer. Expert Opin Pharmacother 2015;16:2293-305. [PMID: 26359224 DOI: 10.1517/14656566.2015.1080238] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
3 Fujiwara-Tani R, Okamoto A, Katsuragawa H, Ohmori H, Fujii K, Mori S, Kishi S, Sasaki T, Nakashima C, Kawahara I, Hojo Y, Nishiguchi Y, Mori T, Mizumoto T, Nagai K, Luo Y, Kuniyasu H. BRAF Mutation Is Associated with Hyperplastic Polyp-Associated Gastric Cancer. Int J Mol Sci 2021;22:12724. [PMID: 34884530 DOI: 10.3390/ijms222312724] [Reference Citation Analysis]
4 Jang HJ, Lee A, Kang J, Song IH, Lee SH. Prediction of genetic alterations from gastric cancer histopathology images using a fully automated deep learning approach. World J Gastroenterol 2021; 27(44): 7687-7704 [PMID: 34908807 DOI: 10.3748/wjg.v27.i44.7687] [Reference Citation Analysis]
5 Pandian J, Ganesan K. Delineation of gastric tumors with activated ERK/MAPK signaling cascades for the development of targeted therapeutics. Exp Cell Res 2022;410:112956. [PMID: 34864005 DOI: 10.1016/j.yexcr.2021.112956] [Reference Citation Analysis]
6 Yu SR, Huang XJ, Zhang YP. Gastric cancer related genes. Shijie Huaren Xiaohua Zazhi 2016; 24(32): 4381-4388 [DOI: 10.11569/wcjd.v24.i32.4381] [Reference Citation Analysis]
7 Park JE, Jin MH, Hur M, Nam AR, Bang JH, Won J, Oh DY, Bang YJ. GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer. Gastric Cancer 2019;22:932-40. [PMID: 30815759 DOI: 10.1007/s10120-019-00943-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Fu XH, Chen ZT, Wang WH, Fan XJ, Huang Y, Wu XB, Huang JL, Wang JX, Lin HJ, Tan XL, Wang L, Wang JP. KRAS G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients. J Cancer. 2019;10:821-828. [PMID: 30854087 DOI: 10.7150/jca.27899] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
9 Lin YL, Chen CH, Liu YK, Huang TH, Tsai NM, Tzou SC, Liao KW. Lipo-PEG-PEI complex as an intracellular transporter for protein therapeutics. Int J Nanomedicine 2019;14:1119-30. [PMID: 30863049 DOI: 10.2147/IJN.S188970] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
10 Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. J Clin Oncol 2015;33:3911-20. [PMID: 26282654 DOI: 10.1200/JCO.2014.59.1503] [Cited by in Crossref: 299] [Cited by in F6Publishing: 200] [Article Influence: 42.7] [Reference Citation Analysis]
11 Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, Ghiringhelli F, de la Fouchardière C, Borg C, Samalin E, Bachet JB, Raoul JL, Miglianico L, Bengrine-Lefèvre L, Dahan L, Lecaille C, Aparicio T, Stanbury T, Perrier H, Cayre A, Laurent-Puig P, Gourgou S, Emile JF, Taïeb J. FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. Eur J Cancer 2019;115:97-106. [PMID: 31129386 DOI: 10.1016/j.ejca.2019.04.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
12 Yamaguchi K, Fuse N, Komatsu Y, Fujii H, Hironaka S, Omuro Y, Muro K, Yasui H, Ueda S, Nishina T, Watanabe M, Ohtsu A. Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer. Jpn J Clin Oncol 2021;51:879-85. [PMID: 33561262 DOI: 10.1093/jjco/hyaa276] [Reference Citation Analysis]
13 Yasuoka H, Nakamura Y, Hirokawa M, Yoshida KI, Anno K, Tori M, Tsujimoto M. A rare case of poorly differentiated thyroid carcinoma probably arising from a nodular goiter. BMC Clin Pathol 2017;17:9. [PMID: 28588422 DOI: 10.1186/s12907-017-0048-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
14 Smolińska M, Grzanka D, Antosik P, Kasperska A, Neska-Długosz I, Jóźwicki J, Klimaszewska-Wiśniewska A. HER2, NF-κB, and SATB1 Expression Patterns in Gastric Cancer and Their Correlation with Clinical and Pathological Parameters. Dis Markers 2019;2019:6315936. [PMID: 31737131 DOI: 10.1155/2019/6315936] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Hedner C, Borg D, Nodin B, Karnevi E, Jirström K, Eberhard J. Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma. PLoS One 2016;11:e0148101. [PMID: 26844548 DOI: 10.1371/journal.pone.0148101] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
16 Jin ZT, Li K, Li M, Ren ZG, Wang FS, Zhu JY, Leng XS, Yu WD. G-protein coupled receptor 34 knockdown impairs the proliferation and migration of HGC-27 gastric cancer cells in vitro. Chin Med J (Engl) 2015;128:545-9. [PMID: 25673461 DOI: 10.4103/0366-6999.151114] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
17 Zeng W, Rao N, Li Q, Wang G, Liu D, Li Z, Yang Y. Genome-wide Analyses on Single Disease Samples for Potential Biomarkers and Biological Features of Molecular Subtypes: A Case Study in Gastric Cancer. Int J Biol Sci 2018;14:833-42. [PMID: 29989098 DOI: 10.7150/ijbs.24816] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Zhou D, Dong L, Yang L, Ma Q, Liu F, Li Y, Xiong S. Identification and analysis of circRNA-miRNA-mRNA regulatory network in hepatocellular carcinoma. IET Syst Biol 2020;14:391-8. [PMID: 33399102 DOI: 10.1049/iet-syb.2020.0061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
19 Gluszek S, Koziel D, Kowalik A, Zięba S, Urbaniak-Wasik S, Wincewicz A, Sulkowski S. KRAS, KIT and TP53 mutations in mother's and daughter's gastric cardia adenocarcinomas. Prz Gastroenterol 2018;13:76-9. [PMID: 29657615 DOI: 10.5114/pg.2018.72572] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Harada K, Baba Y, Shigaki H, Ishimoto T, Miyake K, Kosumi K, Tokunaga R, Izumi D, Ohuchi M, Nakamura K, Kiyozumi Y, Kurashige J, Iwatsuki M, Miyamoto Y, Sakamoto Y, Yoshida N, Watanabe M, Baba H. Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review. BMC Cancer 2016;16:400. [PMID: 27388016 DOI: 10.1186/s12885-016-2422-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
21 Yang Q, Huo S, Sui Y, Du Z, Zhao H, Liu Y, Li W, Wan X, Liu T, Zhang G. Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers. Front Oncol 2018;8:487. [PMID: 30416987 DOI: 10.3389/fonc.2018.00487] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
22 Oh DY, Lee KW, Han SW, Kim JW, Shin JW, Jo SJ, Won J, Hahn S, Lee H, Kim WH, Bang YJ. A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors. Oncologist 2019;24:1037-e636. [PMID: 31164456 DOI: 10.1634/theoncologist.2019-0294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Shen X, Zhao Y, Chen X, Sun H, Liu M, Zhang W, Jiang F, Li P. Associations of PIK3CA mutations with clinical features and prognosis in gastric cancer. Future Oncology 2019;15:1873-94. [DOI: 10.2217/fon-2018-0335] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
24 Youssef O, Sarhadi V, Ehsan H, Böhling T, Carpelan-Holmström M, Koskensalo S, Puolakkainen P, Kokkola A, Knuutila S. Gene mutations in stool from gastric and colorectal neoplasia patients by next-generation sequencing. World J Gastroenterol 2017; 23(47): 8291-8299 [PMID: 29307989 DOI: 10.3748/wjg.v23.i47.8291] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Li S, Zhang H, Wang X, Qu Y, Duan J, Liu R, Deng T, Ning T, Zhang L, Bai M, Zhou L, Wang X, Ge S, Ying G, Ba Y. Direct targeting of HGF by miR-16 regulates proliferation and migration in gastric cancer. Tumor Biol 2016;37:15175-83. [DOI: 10.1007/s13277-016-5390-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
26 Riquelme I, Saavedra K, Espinoza JA, Weber H, García P, Nervi B, Garrido M, Corvalán AH, Roa JC, Bizama C. Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget 2015;6:24750-79. [PMID: 26267324 DOI: 10.18632/oncotarget.4990] [Cited by in Crossref: 78] [Cited by in F6Publishing: 71] [Article Influence: 13.0] [Reference Citation Analysis]
27 Kim K, Lee HW. Expression of Phosphoinositide 3-Kinase p110α and p110β Subunits and PIK3CA Mutation in Patients With Advanced Gastric Carcinoma. Appl Immunohistochem Mol Morphol 2018;26:740-8. [PMID: 28549032 DOI: 10.1097/PAI.0000000000000524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Kim JW, Lee HS, Nam KH, Ahn S, Kim JW, Ahn SH, Park DJ, Kim HH, Lee KW. PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer. Oncotarget. 2017;8:90948-90958. [PMID: 29207615 DOI: 10.18632/oncotarget.18770] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
29 Liang L, Fang JY, Xu J. Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy. Oncogene. 2016;35:1475-1482. [PMID: 26073079 DOI: 10.1038/onc.2015.209] [Cited by in Crossref: 60] [Cited by in F6Publishing: 67] [Article Influence: 8.6] [Reference Citation Analysis]
30 Hu Y, Tao SY, Deng JM, Hou ZK, Liang JQ, Huang QG, Li LH, Li HB, Chen YM, Yi H, Chen XL, Liu H. Prognostic Value of NRAS Gene for Survival of Colorectal Cancer Patients: A Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev. 2018;19:3001-3008. [PMID: 30484984 DOI: 10.31557/apjcp.2018.19.11.3001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]